FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL            |           |  |  |  |  |  |  |  |
|-------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number:             | 3235-0287 |  |  |  |  |  |  |  |
| Estimated average burde | en        |  |  |  |  |  |  |  |
| hours per response:     | 0.5       |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  DOTSON JERROLD DUANE   |   |  |                   |              |  | 2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [ VTGN ] |                   |  |                    |   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify |  |  |  |
|--|---|--|-------------------|--------------|--|--|-------------------|--|--------------------|---|--|---|--|--|--|
| (Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE  |   |  |                   |              | 3. Date of Earliest Transaction (Month/Day/Year) 06/19/2016  |  |                   |  |                    |   |  | X Officer (give title Other (specify below)  CFO AND SECRETARY  |  |  |  |
| (Street) SOUTH FRANCI (City)   | SCO C.  |  | 94080<br>(Zip)    |              | 4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Che Line)  X Form filed by One Reporting Form filed by More than One Person |  |                   |  |                    |   |  | eporting Perso  | n  |  |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |   |  |                   |              |  |  |                   |  |                    |   |  |   |  |  |  |
| 1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  |   |  |                   |              | Execution Date,  |  | Code (Instr.   5) |  |                    | Beneficia   | s Formally (D) (of ollowing (I) (II)   | orm: Direct<br>) or Indirect<br>(Instr. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)                                  |  |  |
|  |   |  |                   |              |  |  |                   | Code V   | Amount             | (A) or<br>(D)   | Price                                  | Transact<br>(Instr. 3 a   |  |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |  |                   |              |  |  |                   |  |                    |   |  |   |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | te Execution Date | Code (Instr. |  |  |                   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |   |  |                   | Co           | de V   | (A)  | (D)               | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)   | \$3.49  | 06/19/2016                                 |                   | А            |  | 75,000   |                   | (1)  | 06/19/2026         | Common<br>Stock   | 75,000                                 | \$0   | 75,000   | D  |  |

## **Explanation of Responses:**

1. 25% of the shares subject to the option shall vest on the one year anniversary of the Grant Date and 1/48th of the shares subject to the option shall vest monthly every month thereafter until all awarded shares are fully vested.

/s/ Jerrold D. Dotson

06/21/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.